Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) Fair Value & Analysis
Healthcare · CN · Market cap 181B CNY (≈ $27.0B) · ISIN CNE100003G67
What is Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A really worth?
A solid business, but trading 15% above our fair value of ¥147.63.
Strengths
Risks
For context
Fair value as of: Aug 20, 2026
From 26 valuation models · updated 16 days ago
Share price +10.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits in the upper half of our model range, so the margin of safety is thin.
- The data supports the verdict: every model runs on fully documented inputs.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range ¥133.98 – ¥448.86 · fair‑value band ¥107.36 – ¥181.85 · the ¥169.91 price screens above the ¥147.63 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) currently trades at ¥169.91, while our model-based Fair Value estimate is ¥147.63, implying the stock looks roughly 15.1% overvalued today. The Quality Score stands at 74/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥176.68 per share, and 8 of the 26 models we run sit above the ¥169.91 price. Bear case: the Asset-Based group reads lowest at ¥21.05, and 18 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A generated revenue of 33.4B CNY at a net margin of 23.5%. Revenue grew 1.4% year over year. It earns a return on equity of 18.5%. The balance sheet holds a net cash position of 16.5B CNY. Fundamentals as of Aug 20, 2026
Our scenario range runs from ¥107.36 (bear case) to ¥181.85 (bull case); at ¥169.91, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −13%, 300760 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥1.52 per share, which is 1.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (¥176.68) versus Asset-Based (¥21.05). Highest evidence: FCF DCF (77).
Notify me when 300760 reaches fair value
Put 300760 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 74 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions in China and internationally. The company offers various products, including patient monitoring, ultrasound, radiology, AED, defibrillation system, anesthesia, CLIA, chemistry, hematology, ventilators, electrocardiograph, endoscope camera system, operating tables, …
Full company description
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions in China and internationally. The company offers various products, including patient monitoring, ultrasound, radiology, AED, defibrillation system, anesthesia, CLIA, chemistry, hematology, ventilators, electrocardiograph, endoscope camera system, operating tables, surgical lights, medical supply units, accessories, infusion system, orthopedics, IT Products, cardiovascular intervention, animal medical, and OEM products. It also provides various solutions, such as M-connect IT, M-connect ER, M-connect ICU, M-connect OR, and M-connect CCU solutions; advanced patient monitoring and intelligent ventilation, emergency ultrasound solutions, and fast defibrillation; customized pendant and critical care ultrasound solutions; precise anesthesia, minimally invasive surgery, infusion system, surgical lights, and anesthesia ultrasound solutions; laboratory diagnostics, medical imaging, and cybersecurity solutions. The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A reported revenue of 33.3B CNY in FY2025 versus 25.3B CNY in FY2021, a compound +7.1%/yr. Reported net income was 8.1B CNY in FY2025, compounding +0.4%/yr from FY2021.
of which total revenue +18.7 % · buybacks/dilution −3.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
300760 screens 15% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| STERIS plc STE | $232.39 | $175.29 | −25% |
Compare Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760) overvalued or undervalued?
What is the fair value of 300760?
What is the quality score of 300760?
What is the revenue of Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A (300760)?
What is the net profit margin of 300760?
Does Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A pay a dividend?
Watch Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A in the live analysis
One click puts Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.